Trial Profile
The prospective, open, multi-center clinical study of Apatinib(Aitan) in non-first-line treating patient with recurrent/metastatic head and neck squamous cell carcinoma
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 23 Jul 2016
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 23 Jul 2016 New trial record